Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-621 in Adults With Recurrent Genital HSV-2 Infection
NCT04979975Phase 2Not yet recruiting
- Sponsor
- United BioPharma
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, single-blind trial of UB-621 in genital herpes (3 arms), sponsored by United BioPharma. Primary endpoint: Time to first recurrence at 26 weeks. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
UB-621
03
Conditions
genital herpes
Beyond the preview
Go deeper on NCT04979975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04979975.